Lipigon Pharmaceuticals AB (LPGO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.806x

Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has a cash flow conversion efficiency ratio of -0.806x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.38 Million ≈ $-686.81K USD) by net assets (Skr7.91 Million ≈ $851.67K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lipigon Pharmaceuticals AB (LPGO) market capitalisation for the company's overall valuation and market capitalisation.

Lipigon Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Lipigon Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lipigon Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their cash flow conversion efficiency. Explore Lipigon Pharmaceuticals AB (LPGO) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
OCA Acquisition Corp NASDAQ:OCAXU	-0.003x
Tekcapital plc LSE:TEK	-0.012x
Safestay PLC LSE:SSTY	0.030x
TAURUS GOLD CORP. F:W1N	N/A
Livento Group Inc. NASDAQ:NUGND	0.001x
AYURCANN HOLDINGS CORP. F:3ZQ0	0.263x
Fiske PLC LSE:FKE	0.090x
ADVANCED INF SERV(ADVANC) STU:NVAA	0.413x

Annual Cash Flow Conversion Efficiency for Lipigon Pharmaceuticals AB (2018–2025)

The table below shows the annual cash flow conversion efficiency of Lipigon Pharmaceuticals AB from 2018 to 2025. View latest Lipigon Pharmaceuticals AB stock price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr7.91 Million ≈ $851.67K	Skr-35.77 Million ≈ $-3.85 Million	-4.520x	-41.57%
2024-12-31	Skr7.76 Million ≈ $835.21K	Skr-24.78 Million ≈ $-2.67 Million	-3.193x	-534.28%
2023-12-31	Skr28.44 Million ≈ $3.06 Million	Skr-14.32 Million ≈ $-1.54 Million	-0.503x	+94.80%
2022-12-31	Skr3.87 Million ≈ $416.58K	Skr-37.47 Million ≈ $-4.03 Million	-9.679x	-529.59%
2021-12-31	Skr22.96 Million ≈ $2.47 Million	Skr-35.30 Million ≈ $-3.80 Million	-1.537x	-131.41%
2020-12-31	Skr12.98 Million ≈ $1.40 Million	Skr-8.62 Million ≈ $-928.19K	-0.664x	+74.08%
2019-12-31	Skr2.17 Million ≈ $233.42K	Skr-5.56 Million ≈ $-598.24K	-2.563x	-166.14%
2018-12-31	Skr-842.00K ≈ $-90.61K	Skr-3.26 Million ≈ $-351.15K	3.875x	--

About Lipigon Pharmaceuticals AB

ST:LPGO Sweden Biotechnology

Market Cap

$97.81K

Skr908.90K SEK

Market Cap Rank

#31503 Global

#748 in Sweden

Share Price

Skr0.00

Change (1 day)

-44.44%

52-Week Range

Skr0.00 - Skr0.15

All Time High

Skr10.15